Raffaele Ornello, MD, University of L’Aquila, Avezzano, Italy, comments on the 2022 update of the European Headache Federation (EHF) guideline on the use of monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway for migraine prevention. Novel insights from randomized controlled clinical trials and real-world studies have improved the knowledge about those treatments. Thus, a guideline update was needed and included evidence-based recommendations on the patient population that will benefit the most from treatment with anti-CGRP antibodies, as well as suggestions regarding the long-term management of those treatments. This interview took place at the 16th European Headache Congress (EHC) in Vienna, Austria.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Dr Ornello’s conflicts of interest include personal fees from Teva, Novartis, and Eli Lilly; non-financial support from Novartis, Allergan/AbbVie, Teva, and Eli Lilly; participation in advisory boards for Eli Lilly; and participation to the Editorial Board of “The Journal of Headache and Pain” and “Frontiers in Neurology”